Increasing the Tumoricidal Activity of Daunomycin-pHPMA Conjugates Using Vitamin B12 as a Targeting Agent
DOI:
https://doi.org/10.6000/1929-2279.2012.01.02.6Keywords:
Vitamin B12, cyanocobalamin, cancer targeting, HPMA, daunomycin.Abstract
Many different types of tumour have previously been shown to over-express cell-surface receptors involved in the uptake of Vitamin B12 (VB12). We have examined the potential of using VB12 as a targeting agent for the delivery of pHPMA-conjugated daunomycin in four murine tumour models. VB12-targeted-duanomycin-HPMA conjugates were found to increase both the number of survivors and the survival time of tumour-bearing mice. The data indicate that VB12 may be highly effective in enhancing the efficacy of polymer-bound cytotoxins, particularly in those tumours that over-express receptors involved in vitamin B12 uptake.
References
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the anti-cancer agent SMANCS. Can Res 1986; 44: 6357-92.
Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1
Thomson AH, Vasey PA, Murray LS, et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer 1999; 81: 99-107. http://dx.doi.org/10.1038/sj.bjc.6690657
Duncan R, Vicent MJ. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv Drug Deliv Rev 2010; 62: 272-82. http://dx.doi.org/10.1016/j.addr.2009.12.005
Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev 2009; 61: 1131-48. http://dx.doi.org/10.1016/j.addr.2009.05.007
Seymour LW, Ulbrich K, Steyger PS, et al. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br J Cancer 1994; 70: 636-41. http://dx.doi.org/10.1038/bjc.1994.363
Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009; 34: 1629-36. http://dx.doi.org/10.3892/ijo_00000293
Rademaker-Lakhai JM, Terret C, Howell SB, et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004; 10(10): 3386-95. http://dx.doi.org/10.1158/1078-0432.CCR-03-0315
Campone M, Rademaker-Lakhai JM, Bennouna J, et al. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol 2007; 60: 523-33. http://dx.doi.org/10.1007/s00280-006-0397-0
Joly F, Madroszyk A, Floquet A, Gedouin D, Bourdel F. Campone M. AP5346 (ProLindacTM), a pH-dependent polymer-vectorized DACH platinum, is active in borderline potentially platinum-sensitive ovarian cancer (OC) patients: results from an ongoing Phase I/II trial. Precedings AACR-NCI-EORTC 2008 Molecular Targets and Cancer Therapeutics Conference, Geneva, Switzerland.
Russell-Jones GJ, McTavish K, McEwan J, Rice JR, Nowotnik D. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 2004; 98: 1625-33. http://dx.doi.org/10.1016/j.jinorgbio.2004.07.009
Nowotnik DP, Cvitkovic E. ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic. Drug Deliv Rev 2009; 61: 1214-9. http://dx.doi.org/10.1016/j.addr.2009.06.004
Rice JR, Gerberich JL, Nowotnik DP, Howell SB. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 2006; 12: 2248-54. http://dx.doi.org/10.1158/1078-0432.CCR-05-2169
Rachmilewitz B, Sulkes A, Rachmilewitz M, Fuks A. Serum transcobalamin II levels in breast carcinoma patients. Israel J Med Sci 1981; 17: 874-79.
Rachmilewitz B, Rachmilewitz M, Moshkowitz B, Gross J. Serum transcobalamin II in myeloid leukemia. J Lab Clin Med 1971; 78: 275-79.
Rachmilewitz B, Sulkes A, Rachmilewitz M, Fuks Z. Serum transcobalamin II levels in breast carcinoma patients. Isr J Med Sci 1981; 17(9-10): 874-8.
Flodh J. Accumulation of labeled vitamin B-12 in some transplanted tumors. Acta Radiol 1968; (Suppl. 284): 55-60.
Flodh J, Ullberg S. Accumulation of labeled vitamin B12 in some transplanted tumours. Int J Cancer 1968; 3: 694-99. http://dx.doi.org/10.1002/ijc.2910030518
Blomquist L, Flodh H, Ullberg S. Uptake of labeled vitamin B12 and 4-Iodophenylalanine in some tumours of mice. Specialia 1969; 15: 294-96.
Amagasaki T, Green R, Jacobsen DW. Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells. Blood 1990; 76: 1380-6.
McLean GR, Pathare PM, Wilbur DS, et al. Cobalamin analogues modulate the growth of leukemia cells in vitro. Cancer Res 1997; 57: 4015-22.
McLean GR, Quadros EV, Rothenberg SP, Morgan AC, Schrader JW, Ziltener HJ. Antibodies to transcobalamin II block in vitro proliferation of leukemic cells. Blood 1997; 89: 235-42.
McLean GR, Williams MJ, Woodhouse CS, Ziltener HJ. Transcobalamin II and in vitro proliferation of leukemic cells. Leuk Lymphoma 1998; 30: 101-9.
Warnock SH, Collins DA, Morton KA. Comparison of tumor uptake and nuclear medicine images of gallium-67, Thallium-201, and
Collins DA, Hogenkamp HPC. Transcobalamin II receptor imaging via radiolabelled diethylene-triaminepentaacetate cobalamin analogues. J Nucl Med 1997; 38: 717-23.
Collins DA, Hogenkamp HPC, O’Connor MK, et al. Biodistribution of radiolabelled adenosylcobalamin in patients diagnosed with various malignancies. Mayo Clin Proc 2000; 75: 568-80. http://dx.doi.org/10.4065/75.6.568
Collins DA, Hogenkamp HPC, Gebhard MK. Tumor imaging via indium 111-labeled DTPA-adenosylcobalamin. Mayo Clin Proc 1999; 74: 687-91. http://dx.doi.org/10.4065/74.7.687
Cannon MJ, McGreevy JM, Holden JA, West FG, Grissom CB. The uptake and distribution o fluorescently labelled cobalamin in neoplastic and healthy breast tissue. Lasers in Surgery. Advanced Characterization, Therapeutics and Systems. Proc SPIE 2000; 3907: 612-15. http://dx.doi.org/10.1117/12.386306
Bauer JA, Morrison BH, Grane RW, Jacobs BS, Dabney S, Gamero AM. Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Natl Cancer Inst 2002; 94: 1010-9. http://dx.doi.org/10.1093/jnci/94.13.1010
Russell-Jones GJ, McTavish K, McEwan JF. Preliminary studies on the selective accumulation of vitamin-targeted polymers within tumours. J Drug Targ 2011; 19(2): 133-9. Epub 2010 May 6. http://dx.doi.org/10.3109/10611861003734027
Russell-Jones GJ. Cellular Targeting. In CRC press. “Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development". Ed Mariko Morishita and Kinam Park 2011 (Manuscript accepted).
Waibel R, Treichler H, Schaefer NG, et al. New derivatives of vitamin B12 show preferential targeting to tumors. Cancer Res 2008; 68: 2904-11. http://dx.doi.org/10.1158/0008-5472.CAN-07-6771
Duncan R, Rejmanova P, Kopecek J, Lloyd JB. Pinocytic uptake and intracellular degradation of N(2-hydroxypropyl) methacrylamide copolymers, a potential drug delivery system. Biochim Biophys Acta 1981; 678: 143-50. http://dx.doi.org/10.1016/0304-4165(81)90058-1
Pinciroli V, Rizzo V, Angelucci F, Tatò M, Vigevani A. 1H-NMR characterization of methacrylamide polymer conjugates with the anti-cancer drug doxorubicin. Magn Reson Chem 1997; 35: 2-8. http://dx.doi.org/10.1002/(SICI)1097-458X(199701)35:1<2::AID-OMR24>3.0.CO;2-D
Kissel M, Peschke P, Subr V, et al. Synthetic macromolecular drug carriers: biodistribution of poly
McEwan JF, Veitch HS, Russell-Jones GJ. Synthesis and Biological Activity of ribose-5’carbamate derivatives of vitamin B12. Bioconj Chem 1999; 10: 1131-36. http://dx.doi.org/10.1021/bc990086p
Russell-Jones GJ, McEwan JF. Vitamin B12 derivatives and methods for their preparation. 1999; USP 6150341.
Mealey KL, Barhoumi R, Burghardt RC, Safe S, Kochevari, DT. Doxycyclin induces expression of P glycoprotein in MCF-7 breast carcinoma cells. Antimicrobiol Agents Chemother 2002; 46: 755-61. http://dx.doi.org/10.1128/AAC.46.3.755-761.2002
Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Canc Res 2004; 64: 7562-69. http://dx.doi.org/10.1158/0008-5472.CAN-03-4046
Riganti C, Miraglia E, Viarisio D, et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Canc Res 2005; 65: 516-25.
Lankelma J, Dekker H, Luque RF, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999; 5: 1703-707.
Jensen KD, Kopečková P, Bridge JHB, Kopeček J. The cytoplasmic escape and nuclear accumulation of endocytosed and microinjected HPMA copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci 2001; 3: article 32. http://dx.doi.org/10.1208/ps030432
Downloads
Published
How to Cite
Issue
Section
